vs
Side-by-side financial comparison of HIVE Digital Technologies Ltd. (HIVE) and RHYTHM PHARMACEUTICALS, INC. (RYTM). Click either name above to swap in a different company.
HIVE Digital Technologies Ltd. is the larger business by last-quarter revenue ($93.1M vs $57.3M, roughly 1.6× RHYTHM PHARMACEUTICALS, INC.). RHYTHM PHARMACEUTICALS, INC. runs the higher net margin — -83.0% vs -98.1%, a 15.1% gap on every dollar of revenue. On growth, HIVE Digital Technologies Ltd. posted the faster year-over-year revenue change (218.6% vs 36.9%). Over the past eight quarters, HIVE Digital Technologies Ltd.'s revenue compounded faster (102.2% CAGR vs 48.5%).
Mastech Digital, Inc. is a digital transformation and information technology (IT) services company headquartered in Pittsburgh, Pennsylvania, providing services to corporations across North America, Middle East, Asian, and Japan.
Rhythm Pharmaceuticals is a biopharmaceutical firm focused on developing and commercializing targeted therapies for rare genetic disorders causing severe unmanageable obesity, including POMC deficiency, LEPR deficiency, and Bardet-Biedl syndrome. It serves patients in North America and Europe who lack effective standard treatments for their chronic life-altering conditions.
HIVE vs RYTM — Head-to-Head
Income Statement — Q3 FY2026 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $93.1M | $57.3M |
| Net Profit | $-91.3M | $-47.5M |
| Gross Margin | -27.1% | 91.6% |
| Operating Margin | — | -82.2% |
| Net Margin | -98.1% | -83.0% |
| Revenue YoY | 218.6% | 36.9% |
| Net Profit YoY | -234.0% | -9.6% |
| EPS (diluted) | $-0.38 | $-0.73 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $93.1M | $57.3M | ||
| Q3 25 | $87.3M | $51.3M | ||
| Q2 25 | $45.6M | $48.5M | ||
| Q1 25 | — | $32.7M | ||
| Q4 24 | $29.2M | $41.8M | ||
| Q3 24 | $22.6M | $33.3M | ||
| Q2 24 | $32.2M | $29.1M | ||
| Q1 24 | — | $26.0M |
| Q4 25 | $-91.3M | $-47.5M | ||
| Q3 25 | $-15.8M | $-52.9M | ||
| Q2 25 | $35.0M | $-46.6M | ||
| Q1 25 | — | $-49.5M | ||
| Q4 24 | $68.2M | $-43.3M | ||
| Q3 24 | $80.0K | $-43.6M | ||
| Q2 24 | $-18.3M | $-32.3M | ||
| Q1 24 | — | $-141.4M |
| Q4 25 | -27.1% | 91.6% | ||
| Q3 25 | 4.7% | 89.3% | ||
| Q2 25 | -13.6% | 88.6% | ||
| Q1 25 | — | 88.8% | ||
| Q4 24 | -43.7% | 90.9% | ||
| Q3 24 | -66.1% | 88.5% | ||
| Q2 24 | -7.4% | 89.9% | ||
| Q1 24 | — | 89.2% |
| Q4 25 | — | -82.2% | ||
| Q3 25 | — | -102.6% | ||
| Q2 25 | — | -93.4% | ||
| Q1 25 | — | -143.7% | ||
| Q4 24 | — | -98.6% | ||
| Q3 24 | — | -132.0% | ||
| Q2 24 | — | -139.2% | ||
| Q1 24 | — | -538.7% |
| Q4 25 | -98.1% | -83.0% | ||
| Q3 25 | -18.1% | -103.1% | ||
| Q2 25 | 76.8% | -96.1% | ||
| Q1 25 | — | -151.4% | ||
| Q4 24 | 233.2% | -103.6% | ||
| Q3 24 | 0.4% | -131.2% | ||
| Q2 24 | -56.7% | -110.9% | ||
| Q1 24 | — | -544.4% |
| Q4 25 | $-0.38 | $-0.73 | ||
| Q3 25 | $-0.07 | $-0.82 | ||
| Q2 25 | $0.18 | $-0.75 | ||
| Q1 25 | — | $-0.81 | ||
| Q4 24 | $0.52 | $-0.71 | ||
| Q3 24 | $0.00 | $-0.73 | ||
| Q2 24 | $-0.17 | $-0.55 | ||
| Q1 24 | — | $-2.35 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | — | $388.9M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $559.3M | $139.1M |
| Total Assets | $624.0M | $480.2M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $388.9M | ||
| Q3 25 | — | $416.1M | ||
| Q2 25 | — | $291.0M | ||
| Q1 25 | — | $314.5M | ||
| Q4 24 | $40.5M | $320.6M | ||
| Q3 24 | $31.7M | $298.4M | ||
| Q2 24 | — | $319.1M | ||
| Q1 24 | — | $201.2M |
| Q4 25 | $559.3M | $139.1M | ||
| Q3 25 | $624.6M | $148.8M | ||
| Q2 25 | $560.5M | $-11.9M | ||
| Q1 25 | — | $18.9M | ||
| Q4 24 | $430.9M | $21.7M | ||
| Q3 24 | $275.5M | $11.2M | ||
| Q2 24 | $268.6M | $39.3M | ||
| Q1 24 | — | $61.6M |
| Q4 25 | $624.0M | $480.2M | ||
| Q3 25 | $693.0M | $506.9M | ||
| Q2 25 | $628.7M | $372.7M | ||
| Q1 25 | — | $386.7M | ||
| Q4 24 | $478.6M | $392.3M | ||
| Q3 24 | $334.7M | $363.6M | ||
| Q2 24 | — | $381.8M | ||
| Q1 24 | — | $258.7M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $46.0M | $-25.4M |
| Free Cash FlowOCF − Capex | — | — |
| FCF MarginFCF / Revenue | — | — |
| Capex IntensityCapex / Revenue | — | — |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $46.0M | $-25.4M | ||
| Q3 25 | $-10.6M | $-26.6M | ||
| Q2 25 | $10.2M | $-23.3M | ||
| Q1 25 | — | $-40.4M | ||
| Q4 24 | $-28.5M | $-18.8M | ||
| Q3 24 | $-2.2M | $-25.2M | ||
| Q2 24 | $-4.4M | $-29.1M | ||
| Q1 24 | — | $-40.7M |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | $-55.5M | — | ||
| Q3 24 | $-34.7M | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | -189.9% | — | ||
| Q3 24 | -153.4% | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 92.5% | — | ||
| Q3 24 | 143.9% | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | 0.29× | — | ||
| Q1 25 | — | — | ||
| Q4 24 | -0.42× | — | ||
| Q3 24 | -26.94× | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
